Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Moodys
Merck
Express Scripts
Colorcon

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR BELVIQ


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Belviq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01880502 ↗ Pharmacokinetic Study of Belviq in Adult Korean Volunteers Completed IlDong Pharmaceutical Co Ltd Phase 1 2013-06-01 A randomized, double-blind, placebo-controlled, single-dose, dose escalation study (Phase I) to evaluate the tolerability and pharmacokinetics of Belviq in adult Korean volunteers.
NCT01962402 ↗ Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study Unknown status Southern California Institute for Research and Education Phase 4 2014-01-01 The purpose of this study is to determine whether lorcaserin is effective for weight reduction in patients with weight gain as a result of antipsychotic medications.
NCT02019264 ↗ A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul Completed Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization Phase 4 2014-01-24 This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
NCT02019264 ↗ A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul Completed Eisai Inc. Phase 4 2014-01-24 This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
NCT02022956 ↗ Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age Completed Arena Pharmaceuticals Phase 1 2013-12-01 The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old
NCT02022956 ↗ Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age Completed Eisai Inc. Phase 1 2013-12-01 The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Belviq

Condition Name

Condition Name for Belviq
Intervention Trials
Obesity 5
Overweight 3
Smoking Cessation 3
Weight Gain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Belviq
Intervention Trials
Disease 7
Weight Loss 5
Overweight 5
Tobacco Use Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Belviq

Trials by Country

Trials by Country for Belviq
Location Trials
United States 99
New Zealand 6
Australia 6
Canada 5
Mexico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Belviq
Location Trials
California 6
New York 6
North Carolina 6
Virginia 5
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Belviq

Clinical Trial Phase

Clinical Trial Phase for Belviq
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Belviq
Clinical Trial Phase Trials
Completed 11
Terminated 10
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Belviq

Sponsor Name

Sponsor Name for Belviq
Sponsor Trials
National Institute on Drug Abuse (NIDA) 8
Mayo Clinic 3
Virginia Commonwealth University 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Belviq
Sponsor Trials
Other 23
NIH 11
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
McKinsey
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.